Needham Maintains Buy on TransMedics Group, Lowers Price Target to $106
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $142 to $106.
Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $142 to $106.